Literature DB >> 11532336

Expression of receptor-activity modifying protein (RAMP) mRNAs in the mouse brain.

T Ueda1, S Ugawa, Y Saishin, S Shimada.   

Abstract

Receptor activity modifying proteins (RAMPs) comprise a family of accessory proteins for G protein-coupled receptors (GPCRs). They function as receptor modulators that determine the ligand specificity of receptors for calcitonin gene-related peptide (CGRP), amylin and adrenomedullin (ADM). Here we demonstrate for the first time the characteristic distributions of the RAMP family mRNAs in the brain. Northern blot analysis revealed that mRAMP 1 and 3 mRNAs were intensely expressed in the brain, but mRAMP2 mRNA less abundantly. In situ hybridization studies showed the heterogenous and unique distributions of mRAMP mRNAs; RAMP1 mRNA was widely expressed throughout the brain including the cerebral cortex, caudate putamen, amygdaloid complex, hippocampus, cerebellum and ependyma, mRAMP2 was most abundant in the hippocampus, cerebellum, pia mater and blood vessels, while mRAMP3 was specifically distributed in a variety of thalamic nuclei and the cerebellum. In addition, RAMP1 and -3 genes were also detected in the subfornical organ and area postrema, which are members of circumventricular organs lacking blood-brain barrier. The present results help in understanding the diversification and regulation of receptor functions for calcitonin family peptides, and potentially other GPCRs in the brain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11532336     DOI: 10.1016/s0169-328x(01)00179-6

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  18 in total

1.  Pharmacological characterization of rat amylin receptors: implications for the identification of amylin receptor subtypes.

Authors:  R J Bailey; C S Walker; A H Ferner; K M Loomes; G Prijic; A Halim; L Whiting; A R J Phillips; D L Hay
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

Review 2.  Pancreatic signals controlling food intake; insulin, glucagon and amylin.

Authors:  Stephen C Woods; Thomas A Lutz; Nori Geary; Wolfgang Langhans
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-07-29       Impact factor: 6.237

3.  Effect of Valsartan on Cerebellar Adrenomedullin System Dysregulation During Hypertension.

Authors:  Leticia Figueira; Anita Israel
Journal:  Cerebellum       Date:  2017-02       Impact factor: 3.847

4.  Possible sites of action of the new calcitonin gene-related peptide receptor antagonists.

Authors:  Sajedeh Eftekhari; Lars Edvinsson
Journal:  Ther Adv Neurol Disord       Date:  2010-11       Impact factor: 6.570

Review 5.  Control of energy homeostasis by amylin.

Authors:  Thomas A Lutz
Journal:  Cell Mol Life Sci       Date:  2011-12-23       Impact factor: 9.261

6.  Dysregulation of Cerebellar Adrenomedullin Signaling During Hypertension.

Authors:  Leticia Figueira; Anita Israel
Journal:  J Mol Neurosci       Date:  2017-06-26       Impact factor: 3.444

Review 7.  Gut hormones such as amylin and GLP-1 in the control of eating and energy expenditure.

Authors:  T A Lutz
Journal:  Int J Obes Suppl       Date:  2016-11-16

8.  Early postnatal amylin treatment enhances hypothalamic leptin signaling and neural development in the selectively bred diet-induced obese rat.

Authors:  Miranda D Johnson; Sebastien G Bouret; Ambrose A Dunn-Meynell; Christina N Boyle; Thomas A Lutz; Barry E Levin
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-09-14       Impact factor: 3.619

9.  Stimulation of Posterior Thalamic Nuclei Induces Photophobic Behavior in Mice.

Authors:  Levi P Sowers; Mengya Wang; Brandon J Rea; Rebecca J Taugher; Adisa Kuburas; Youngcho Kim; John A Wemmie; Christopher S Walker; Debbie L Hay; Andrew F Russo
Journal:  Headache       Date:  2020-08-04       Impact factor: 5.887

10.  Comparison of the expression of calcitonin receptor-like receptor (CRLR) and receptor activity modifying proteins (RAMPs) with CGRP and adrenomedullin binding in cell lines.

Authors:  Tejal Choksi; Debbie L Hay; Stephen Legon; David R Poyner; Stefanie Hagner; Stephen R Bloom; David M Smith
Journal:  Br J Pharmacol       Date:  2002-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.